Is Pegasys Approved for Hepatitis B?
Yes, Pegasys (peginterferon alfa-2a) is FDA-approved for chronic hepatitis B in adults and children aged 3 and older. It treats both HBeAg-positive and HBeAg-negative forms, aiming to achieve viral suppression and liver function normalization.[1][2]
How Does Pegasys Work for Hep B?
Pegasys, a pegylated interferon, boosts the immune response against the hepatitis B virus (HBV). It's injected subcutaneously once weekly for 48 weeks in HBeAg-positive patients or 24-48 weeks in HBeAg-negative cases, often combined with other antivirals like tenofovir for better outcomes.[1][3]
When Is Pegasys Recommended Over Other Hep B Treatments?
Guidelines from AASLD and EASL recommend Pegasys for patients who prefer finite treatment duration over lifelong nucleoside analogs like entecavir or tenofovir, especially if they have low viral loads or genotype A HBV. It's less favored now due to oral alternatives with higher response rates.[3][4]
What Are Common Side Effects in Hep B Patients?
Patients report flu-like symptoms (fever, fatigue, muscle pain), depression, anemia, and thyroid issues. Up to 30% discontinue due to intolerance. Monitoring for psychiatric effects and blood counts is required.[1][2]
How Does Pegasys Compare to Hep C Use?
Pegasys was a frontline treatment for hepatitis C (often with ribavirin) until direct-acting antivirals displaced it. For hep B, its role persists but is niche; hep C cures exceed 95% with newer drugs, while hep B seroconversion with Pegasys is 20-40%.[3][5]
Current Availability and Patent Status
Pegasys, made by Roche/Genentech, remains available but faces generic competition. Key U.S. patents expired around 2020-2025; check DrugPatentWatch.com for exact expiry dates and litigation updates.[6]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103949s5215lbl.pdf
[2] Drugs.com: https://www.drugs.com/pegasys.html
[3] AASLD Guidelines: https://www.aasld.org/practice-guidelines/chronic-hepatitis-b
[4] EASL Guidelines: https://easl.eu/publication/hepatitis-b-guidelines/
[5] NIH Hep C Info: https://www.hcv.gov/treatment
[6] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/PEGASYS